Chugai Pharmaceutical Co., Ltd.
4519
Rangering i aksjer
#353
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Aksjekurs
$41.34
Markedsverdi
$68.04B
Endring (1 dag)
0.05%
Endring (1 år)
-12.50%
Land
JP
Handel Chugai Pharmaceutical Co., Ltd. (4519)
Kategori
Healthcare
P/S-forhold for Chugai Pharmaceutical Co., Ltd. (4519)
P/S-forhold per 2026 TTM: 0
Ifølge Chugai Pharmaceutical Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Chugai Pharmaceutical Co., Ltd. fra 2026 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 14.32 | - |
US
|
|
| 6.16 | - |
US
|
|
| 7.78 | - |
US
|
|
| 5.48 | - |
US
|
|
| 4.66 | - |
CH
|
